Spots Global Cancer Trial Database for recurrent fallopian tube carcinoma

Every month we try and update this database with for recurrent fallopian tube carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT03691376	Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Platinum-Sensit... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim...	Aldesleukin Autologous NY-E... Cellular Therap... Melphalan	18 Years -	Roswell Park Cancer Institute
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	NCT00671788	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Dasatinib Laboratory Biom...	18 Years -	GOG Foundation
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	NCT02996825	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative...	Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological...	-	City of Hope Medical Center
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02839707	Fallopian Tube ... Ovarian High Gr... Ovarian Seromuc... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Atezolizumab Bevacizumab Computed Tomogr... Pegylated Lipos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT04781088	Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Lenvatinib Paclitaxel Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01074411	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate...	Bortezomib Carboplatin Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02446600	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima...	Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT03586661	Deleterious BRC... Deleterious BRC... Endometrial Ade... High Grade Ovar... Platinum-Resist... Primary Periton... Progressive Dis... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Copanlisib Niraparib	18 Years -	M.D. Anderson Cancer Center
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02901899	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Guadecitabine Laboratory Biom... Pembrolizumab	18 Years -	Northwestern University
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	NCT05672095	Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Niraparib Questionnaire A... Selenium	18 Years -	City of Hope Medical Center
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent	NCT02470559	Malignant Ovari... Malignant Ovari... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Aldesleukin HER2Bi-Armed Ac... Laboratory Biom... Sargramostim	18 Years -	Barbara Ann Karmanos Cancer Institute
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy	NCT01492920	Fatigue Malignant Ovari... Neuropathy Neurotoxicity S... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Pain Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Acetyl-L-Carnit... Placebo Questionnaire A... Quality-of-Life...	18 Years -	GOG Foundation
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02315430	Fallopian Tube ... Ovarian Clear C... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cabozantinib S-... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
A Study of FRaDCs for Ovarian Cancer	NCT05920798	Fallopian Tube ... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Multi-epitope F... Pembrolizumab Pheresis	18 Years -	Mayo Clinic
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	NCT01294293	Malignant Ovari... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate...	TLR8 Agonist VT... Diagnostic Labo... Pharmacological... Pegylated Lipos... Paclitaxel	18 Years -	GOG Foundation
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	NCT04092270	Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib	18 Years -	National Cancer Institute (NCI)
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT01720173	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Dalantercept Laboratory Biom...	18 Years -	GOG Foundation
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01074411	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate...	Bortezomib Carboplatin Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT01540565	BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Epithel... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Veliparib	18 Years -	National Cancer Institute (NCI)
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	NCT01010126	Adult Hepatocel... Advanced Adult ... Endometrial Ser... Localized Non-R... Lung Carcinoid ... Malignant Pancr... Malignant Pancr... Malignant Pancr... Malignant Pancr... Metastatic Dige... Ovarian Carcino... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Pancreatic Alph... Pancreatic Beta... Pancreatic Delt... Pancreatic G-Ce... Pancreatic Poly... Recurrent Adult... Recurrent Diges... Recurrent Fallo... Recurrent Ovari... Recurrent Pancr... Recurrent Prima... Recurrent Uteri... Regional Digest... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino...	Bevacizumab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	NCT02996825	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative...	Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological...	-	City of Hope Medical Center
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02923739	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Emactuzumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT03026062	Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim...	Durvalumab Tremelimumab	18 Years -	M.D. Anderson Cancer Center
Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers	NCT06295965	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Non-Interventio...	-	University of Washington
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02101775	Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Collecting Tumor Samples From Patients With Gynecological Tumors	NCT00897442	Borderline Ovar... Borderline Ovar... Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Childhood Embry... Childhood Malig... Endometrioid St... Gestational Tro... Malignant Mesot... Malignant Ovari... Melanoma Neoplasm of Unc... Ovarian Brenner... Ovarian Clear C... Ovarian Serous ... Paget Disease o... Recurrent Cervi... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... Stage I Ovarian... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Cervic... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage III Borde... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Border... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Stage IVB Vulva... Uterine Corpus ... Uterine Corpus ... Vulvar Squamous...	Laboratory Biom...	-	GOG Foundation
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT01716715	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cabozantinib S-... Laboratory Biom... Paclitaxel	18 Years -	National Cancer Institute (NCI)
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study	NCT00968799	Epithelial Ovar... Fallopian Tube ...	Hyperthermic in... Cytoreduction Cisplatin	18 Years - 70 Years	Cantonal Hospital of St. Gallen
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	NCT05691504	Advanced Endome... Metastatic Endo... Metastatic Fall... Metastatic Plat... Metastatic Prim... Recurrent Endom... Recurrent Fallo... Recurrent Plati... Recurrent Prima... Stage III Uteri... Stage IV Uterin...	Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pelcitoclax	18 Years -	National Cancer Institute (NCI)
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT02283658	Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Undifferentiate...	Everolimus Laboratory Biom... Letrozole	18 Years -	Mayo Clinic
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT04387227	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Carboplatin Pembrolizumab Computed Tomogr... Magnetic Resona... Biospecimen Col...	18 Years -	University of Washington
Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT02111941	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Undifferentiate... Undifferentiate...	Laboratory Biom... Multi-epitope F...	18 Years -	Mayo Clinic
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer	NCT02275039	Recurrent Ovari... Recurrent Fallo... Recurrent Prima...	modified vaccin... gemcitabine hyd... laboratory biom...	18 Years -	City of Hope Medical Center
Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy	NCT00602277	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Wild-type Reovi...	18 Years -	National Cancer Institute (NCI)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	NCT05554328	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Echocardiograph... Multigated Acqu... Olaparib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
Collecting Tumor Samples From Patients With Gynecological Tumors	NCT00897442	Borderline Ovar... Borderline Ovar... Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Childhood Embry... Childhood Malig... Endometrioid St... Gestational Tro... Malignant Mesot... Malignant Ovari... Melanoma Neoplasm of Unc... Ovarian Brenner... Ovarian Clear C... Ovarian Serous ... Paget Disease o... Recurrent Cervi... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... Stage I Ovarian... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Cervic... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage III Borde... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Border... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Stage IVB Vulva... Uterine Corpus ... Uterine Corpus ... Vulvar Squamous...	Laboratory Biom...	-	GOG Foundation
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer	NCT02068794	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Mesenchymal Ste... Oncolytic Measl...	18 Years -	Mayo Clinic
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02948101	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Anti-CSF1 Monoc... Cyclophosphamid... Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT03029598	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Carboplatin Laboratory Biom... Pembrolizumab	18 Years -	University of Washington
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	NCT04213794	Malignant Abdom... Malignant Pelvi... Recurrent Colon... Recurrent Desmo... Recurrent Fallo... Recurrent Gastr... Recurrent Lipos... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Recurrent Recta... Recurrent Rhabd... Recurrent Sarco... Refractory Colo... Refractory Desm... Refractory Fall... Refractory Gast... Refractory Lipo... Refractory Mali... Refractory Ovar... Refractory Prim... Refractory Rect... Refractory Rhab... Refractory Sarc... Resectable Lipo... Resectable Mali... Resectable Sarc...	Cisplatin Cytoreductive S... Doxorubicin Hyperthermic In... Sodium Thiosulf... Computed Tomogr... Magnetic Resona... Positron Emissi... Biospecimen Col...	1 Year - 25 Years	Mayo Clinic
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer	NCT01283035	Ovarian Sarcoma Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Akt Inhibitor M... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT00888615	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Elesclomol Sodi... Paclitaxel	18 Years -	GOG Foundation
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02315430	Fallopian Tube ... Ovarian Clear C... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cabozantinib S-... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers	NCT03968406	Malignant Femal... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Vagin... Stage IV Cervic... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IV Vagina... Stage IVA Cervi... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri... Stage IVB Vagin...	Quality-of-Life... Radiation Thera... Talazoparib	18 Years -	M.D. Anderson Cancer Center
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	NCT02142803	Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT03029598	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Carboplatin Laboratory Biom... Pembrolizumab	18 Years -	University of Washington
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	NCT01264432	Adult Solid Neo... Peritoneal Carc... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Quality-of-Life... Radiation Thera... Veliparib	18 Years -	National Cancer Institute (NCI)
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	NCT05672095	Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Niraparib Questionnaire A... Selenium	18 Years -	City of Hope Medical Center
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02595892	Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Berzosertib Gemcitabine Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02948101	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Anti-CSF1 Monoc... Cyclophosphamid... Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients	NCT03539406	Recurrent Ovari... Recurrent Fallo... Recurrent Prima...	UCB-NK cells Chemotherapy	18 Years - 75 Years	Radboud University Medical Center
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01489371	Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... PEG-PEI-cholest... Pegylated Lipos...	18 Years -	GOG Foundation
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02595892	Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Berzosertib Gemcitabine Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	NCT03552471	BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist...	Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy...	18 Years -	Ohio State University Comprehensive Cancer Center
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	NCT02502266	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cediranib Cediranib Malea... Computed Tomogr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Questionnaire A... Topotecan Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer	NCT02275039	Recurrent Ovari... Recurrent Fallo... Recurrent Prima...	modified vaccin... gemcitabine hyd... laboratory biom...	18 Years -	City of Hope Medical Center
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF	NCT03604315	Breast Carcinom... Fallopian Tube ... Ovarian Carcino... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Solid Neoplasm	Computed Tomogr... Computed Tomogr... Fludeoxyglucose... Fluorine F 18 F... Positron Emissi... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	NCT05554328	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Echocardiograph... Multigated Acqu... Olaparib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer	NCT04469764	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Abemaciclib Anastrozole Letrozole	-	Jonsson Comprehensive Cancer Center
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02923739	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Emactuzumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT03579316	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Olaparib Ceralasertib	18 Years -	M.D. Anderson Cancer Center
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01489371	Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... PEG-PEI-cholest... Pegylated Lipos...	18 Years -	GOG Foundation
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer	NCT02059265	Endometrial Cle... Ovarian Clear C... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri...	Dasatinib Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	NCT01459380	Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate...	Bevacizumab Carboplatin Laboratory Biom... Pegylated Lipos... Veliparib	18 Years -	National Cancer Institute (NCI)
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	NCT02142803	Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT01606241	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIA Breas... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Breas... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Brea... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Brea... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Brea... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Cyclophosphamid... Laboratory Biom... Multi-epitope F...	18 Years -	Mayo Clinic
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer	NCT02657928	Estrogen Recept... Postmenopausal Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri...	Laboratory Biom... Letrozole Ribociclib	18 Years -	Mayo Clinic
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	NCT03508570	Malignant Perit... Malignant Retro... Metastatic Cerv... Metastatic Endo... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Peritoneal Carc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Ipilimumab Laboratory Biom... Nivolumab Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	NCT00565851	Clear Cell Aden... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Mucinous Adenoc... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate...	Bevacizumab Carboplatin Docetaxel Gemcitabine Hyd... Laboratory Biom... Paclitaxel Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab	NCT03412630	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Computed Tomogr...	18 Years -	Eastern Cooperative Oncology Group
Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02756130	High Grade Fall... High Grade Ovar... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Birinapant Carboplatin Laboratory Biom... Pharmacological...	18 Years -	Jonsson Comprehensive Cancer Center
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	NCT01459380	Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate...	Bevacizumab Carboplatin Laboratory Biom... Pegylated Lipos... Veliparib	18 Years -	National Cancer Institute (NCI)
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF	NCT03604315	Breast Carcinom... Fallopian Tube ... Ovarian Carcino... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Solid Neoplasm	Computed Tomogr... Computed Tomogr... Fludeoxyglucose... Fluorine F 18 F... Positron Emissi... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	NCT04919629	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Serous ... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Biopsy Biospecimen Col... Pegcetacoplan Pembrolizumab Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02312245	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Gemcitabine Hyd... Paclitaxel Pegylated Lipos... Topotecan Hydro...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: